Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/01/23
Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should KnowZacks Investment Research • 11/23/23
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back PainPRNewsWire • 11/20/23
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 GuidancePRNewsWire • 11/01/23
Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/25/23
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation TherapyPRNewsWire • 09/18/23
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic NeuropathyPRNewsWire • 08/16/23
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 GuidancePRNewsWire • 08/01/23
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual ConferencePRNewsWire • 07/13/23
Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific SessionsPRNewsWire • 06/23/23